|
Market Closed -
Nasdaq
16:00:00 2026-10-23 EDT
|
5-day change | 1st Jan Change | ||
| 2.280 USD | -25.00% |
|
-13.31% | -29.41% |
| 10-16 | Top Premarket Gainers | MT |
| 10-13 | Alaunos Therapeutics Enters into Agreement and Plan of Merger with Velaris Therapeutics | CI |
Company Valuation: Alaunos Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 536.6 | 234 | 155.4 | 16.98 | 3.05 | 7.209 |
| Change | - | -56.4% | -33.56% | -89.08% | -82.04% | 136.32% |
| Enterprise Value (EV) 1 | 426.3 | 187.3 | 135.9 | 10.92 | 1.959 | 5.824 |
| Change | - | -56.08% | -27.43% | -91.96% | -82.06% | 197.23% |
| P/E | -6.61x | -2.97x | -3.74x | -0.48x | -0.65x | -1.47x |
| PBR | 4.35x | 4.04x | 4.03x | 2.69x | 1.48x | 3.52x |
| PEG | - | 0.8x | 0.1x | 0x | 0x | 0.1x |
| Capitalization / Revenue | - | 587,819,588x | 53,196,617x | 3,396,281,000x | 305,038,500x | 1,441,761,400x |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -5.38x | -2.52x | -4.53x | -0.42x | -0.41x | -1.38x |
| EV / EBIT | -5.31x | -2.44x | -4.15x | -0.38x | -0.41x | -1.38x |
| EV / FCF | -11.8x | -5.36x | -4.86x | -2.14x | -0.59x | -7.73x |
| FCF Yield | -8.45% | -18.7% | -20.6% | -46.7% | -168% | -12.9% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -57.22 | -55.1 | -26.06 | -22 | -2.922 | -2.198 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | 0.398 | 2.922 | 0.005 | 0.01 | 0.005 |
| EBITDA 1 | -79.23 | -74.21 | -29.98 | -26.18 | -4.81 | -4.218 |
| EBIT 1 | -80.36 | -76.81 | -32.74 | -28.49 | -4.812 | -4.225 |
| Net income 1 | -79.98 | -78.75 | -37.73 | -35.14 | -4.679 | -4.176 |
| Net Debt 1 | -110.3 | -46.69 | -19.55 | -6.062 | -1.091 | -1.385 |
| Reference price 2 | 378.000 | 163.500 | 97.365 | 10.605 | 1.905 | 3.230 |
| Nbr of stocks (in thousands) | 1,420 | 1,431 | 1,596 | 1,601 | 1,601 | 2,232 |
| Announcement Date | 3/1/21 | 3/30/22 | 3/7/23 | 4/1/24 | 3/31/25 | 3/31/26 |
1USD in Million2USD
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 5.79M | |
| 18.83x | 6.63x | 13.18x | 1.58% | 64.69B | |
| 30.16x | 7.93x | 26.43x | 0.05% | 54.78B | |
| 36.79x | 6.53x | 19.51x | 0.88% | 53.49B | |
| 35.59x | 3.45x | 14.87x | -.--% | 45.98B | |
| 49.71x | 5.74x | 31.52x | -.--% | 42.94B | |
| -19.41x | 187.75x | -20.66x | -.--% | 40.08B | |
| 28.93x | 8.21x | 21.27x | 0.37% | 33.52B | |
| 32.66x | 5.97x | 20.09x | -.--% | 23.67B | |
| 27.67x | 5.83x | 15.12x | -.--% | 23.97B | |
| Average | 26.77x | 26.45x | 15.70x | 0.32% | 38.31B | |
| Weighted average by Cap. | 26.72x | 25.32x | 15.93x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- TCRT Stock
- Valuation Alaunos Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
